User login
Highlights in Breast Cancer From SITC 2022
Jennifer Guerriero, PhD, from Brigham and Women's Hospital in Boston, Massachusetts, shares highlights in breast cancer from the 37th Annual Meeting of the Society for Immunotherapy of Cancer.
She begins with a study of the tumor microenvironment that found a range of MHC-1 expression across breast cancer subtypes. Crucially, expression appears to affect the local immune landscape and response to immunotherapy.
Next, she looks at a study that showed that the tyrosine kinase Ron affects T-cell recruitment into sites of metastatic breast cancer, offering a potential therapeutic target via Ron kinase inhibitors.
Dr Guerriero moves on to a study exploring tumor antigen-specific antibody responses in patients with metastatic triple-negative breast cancer patients and their association with immunotherapy outcomes.
This is followed by a phase 1/2 trial in which an in situ anti-cancer vaccine was created with a combination of four treatments, achieving responses in heavily pretreated patients.
Dr Guerriero ends with a series of posters on CT-0508, a novel anti-HER2 chimeric antigen receptor macrophage therapy, that showed encouraging activity in targeting HER2 overexpressing tumors.
--
Assistant Professor, Department of Surgery, Division of Breast Surgery, Brigham and Women's Hospital, Boston, Massachusetts
Jennifer L. Guerriero, PhD, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Mersana; Duke St Bio; AstraZeneca; OncoOne
Received research grant from: Merck
Jennifer Guerriero, PhD, from Brigham and Women's Hospital in Boston, Massachusetts, shares highlights in breast cancer from the 37th Annual Meeting of the Society for Immunotherapy of Cancer.
She begins with a study of the tumor microenvironment that found a range of MHC-1 expression across breast cancer subtypes. Crucially, expression appears to affect the local immune landscape and response to immunotherapy.
Next, she looks at a study that showed that the tyrosine kinase Ron affects T-cell recruitment into sites of metastatic breast cancer, offering a potential therapeutic target via Ron kinase inhibitors.
Dr Guerriero moves on to a study exploring tumor antigen-specific antibody responses in patients with metastatic triple-negative breast cancer patients and their association with immunotherapy outcomes.
This is followed by a phase 1/2 trial in which an in situ anti-cancer vaccine was created with a combination of four treatments, achieving responses in heavily pretreated patients.
Dr Guerriero ends with a series of posters on CT-0508, a novel anti-HER2 chimeric antigen receptor macrophage therapy, that showed encouraging activity in targeting HER2 overexpressing tumors.
--
Assistant Professor, Department of Surgery, Division of Breast Surgery, Brigham and Women's Hospital, Boston, Massachusetts
Jennifer L. Guerriero, PhD, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Mersana; Duke St Bio; AstraZeneca; OncoOne
Received research grant from: Merck
Jennifer Guerriero, PhD, from Brigham and Women's Hospital in Boston, Massachusetts, shares highlights in breast cancer from the 37th Annual Meeting of the Society for Immunotherapy of Cancer.
She begins with a study of the tumor microenvironment that found a range of MHC-1 expression across breast cancer subtypes. Crucially, expression appears to affect the local immune landscape and response to immunotherapy.
Next, she looks at a study that showed that the tyrosine kinase Ron affects T-cell recruitment into sites of metastatic breast cancer, offering a potential therapeutic target via Ron kinase inhibitors.
Dr Guerriero moves on to a study exploring tumor antigen-specific antibody responses in patients with metastatic triple-negative breast cancer patients and their association with immunotherapy outcomes.
This is followed by a phase 1/2 trial in which an in situ anti-cancer vaccine was created with a combination of four treatments, achieving responses in heavily pretreated patients.
Dr Guerriero ends with a series of posters on CT-0508, a novel anti-HER2 chimeric antigen receptor macrophage therapy, that showed encouraging activity in targeting HER2 overexpressing tumors.
--
Assistant Professor, Department of Surgery, Division of Breast Surgery, Brigham and Women's Hospital, Boston, Massachusetts
Jennifer L. Guerriero, PhD, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Mersana; Duke St Bio; AstraZeneca; OncoOne
Received research grant from: Merck
